| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.466 | 0.103 | 0.466 | Antiinflammatory | 0.383 0.15 DBMET03213 | ||
| 0.326 | 0.005 | 0.356 | Janus tyrosine kinase 2 inhibitor | 0.356 0.005 DBMET03213 | DBMET03213 | |
| 0.34 | 0.036 | 0.366 | Tyrosine kinase inhibitor | 0.366 0.032 DBMET03213 | DBMET03213 | |
| 0.365 | 0.075 | 0.511 | Toll-Like receptor 7 agonist | 0.511 0.03 DBMET03213 | DBMET03213 | |
| 0.357 | 0.079 | 0.513 | Toll-Like receptor agonist | 0.513 0.029 DBMET03213 | DBMET03213 | |
| 0.27 | 0.005 | 0.27 | Tyk2 inhibitor | 0.162 0.012 DBMET03213 | ||
| 0.355 | 0.114 | 0.355 | Beta lactamase inhibitor | |||
| 0.278 | 0.086 | 0.313 | Nootropic | 0.313 0.068 DBMET03213 | DBMET03213 | |
| 0.196 | 0.005 | 0.196 | Janus tyrosine kinase 1 inhibitor | 0.149 0.01 DBMET03213 | ||
| 0.166 | 0.016 | 0.186 | Janus tyrosine kinase 3 inhibitor | 0.186 0.013 DBMET03213 | DBMET03213 | |
| 0.157 | 0.008 | 0.184 | Focal adhesion kinase 1 inhibitor | 0.184 0.005 DBMET03213 | DBMET03213 | |
| 0.147 | 0.01 | 0.147 | Cannabinoid CB2 receptor agonist | |||
| 0.144 | 0.014 | 0.144 | Cannabinoid receptor agonist | |||
| 0.123 | 0.038 | 0.123 | Hedgehog signaling inhibitor | |||
| 0.261 | 0.177 | 0.336 | MAP kinase kinase 6 inhibitor | 0.336 0.103 DBMET03213 | DBMET03213 | |
| 0.113 | 0.031 | 0.184 | AXL receptor tyrosine kinase inhibitor | 0.184 0.01 DBMET03213 | DBMET03213 | |
| 0.099 | 0.018 | 0.099 | Tyrosine-protein kinase EMT inhibitor | |||
| 0.207 | 0.145 | 0.215 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.215 0.126 DBMET03213 | DBMET03213 | |
| 0.126 | 0.068 | 0.184 | Protein kinase (CK1) delta inhibitor | 0.184 0.035 DBMET03213 | DBMET03213 | |
| 0.076 | 0.025 | 0.09 | Cyclin-dependent kinase 6 inhibitor | 0.09 0.014 DBMET03213 | DBMET03213 | |
| 0.094 | 0.045 | 0.095 | ALK inhibitor | 0.095 0.044 DBMET03213 | DBMET03213 | |
| 0.148 | 0.101 | 0.148 | Cyclin-dependent kinase 3 inhibitor | |||
| 0.09 | 0.048 | 0.09 | I kappa B kinase inhibitor | 0.09 0.048 DBMET03213 | ||
| 0.062 | 0.02 | 0.08 | Antiviral (Hepatitis D) | 0.08 0.009 DBMET03213 | DBMET03213 | |
| 0.064 | 0.024 | 0.064 | Chemokine receptor agonist | |||
| 0.092 | 0.053 | 0.092 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | |||
| 0.07 | 0.032 | 0.07 | I kappa B kinase 2 inhibitor | 0.068 0.035 DBMET03213 | ||
| 0.076 | 0.039 | 0.089 | MAP kinase kinase 8 inhibitor | 0.089 0.028 DBMET03213 | DBMET03213 | |
| 0.064 | 0.029 | 0.118 | Phosphatidylinositol 3-kinase gamma inhibitor | 0.118 0.012 DBMET03213 | DBMET03213 | |
| 0.104 | 0.071 | 0.123 | CDC-like kinase 3 inhibitor | 0.123 0.04 DBMET03213 | DBMET03213 | |
| 0.074 | 0.045 | 0.086 | Phosphodiesterase VIII inhibitor | 0.086 0.026 DBMET03213 | DBMET03213 | |
| 0.069 | 0.04 | 0.134 | Adenosine A2 receptor antagonist | 0.134 0.019 DBMET03213 | DBMET03213 | |
| 0.12 | 0.091 | 0.217 | Protein kinase (CK1) inhibitor | 0.217 0.035 DBMET03213 | DBMET03213 | |
| 0.084 | 0.057 | 0.116 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.116 0.027 DBMET03213 | DBMET03213 | |
| 0.027 | 0.004 | 0.063 | Egl nine homolog 2 inhibitor | 0.063 0.003 DBMET03213 | DBMET03213 | |
| 0.126 | 0.104 | 0.213 | Heat shock protein 90 antagonist | 0.213 0.032 DBMET03213 | DBMET03213 | |
| 0.144 | 0.126 | 0.227 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.227 0.058 DBMET03213 | DBMET03213 | |
| 0.061 | 0.044 | 0.149 | Adenosine A2a receptor antagonist | 0.149 0.015 DBMET03213 | DBMET03213 | |
| 0.036 | 0.021 | 0.036 | CXC chemokine receptor agonist | |||
| 0.067 | 0.053 | 0.067 | Syk tyrosine kinase inhibitor | |||
| 0.108 | 0.095 | 0.139 | Phosphodiesterase inhibitor | 0.139 0.066 DBMET03213 | DBMET03213 | |
| 0.038 | 0.029 | 0.044 | Protein kinase (CK1) epsilon inhibitor | 0.044 0.019 DBMET03213 | DBMET03213 | |
| 0.075 | 0.067 | 0.075 | Phosphodiesterase IV inhibitor | 0.074 0.068 DBMET03213 | ||
| 0.055 | 0.047 | 0.125 | Phosphatidylinositol kinase inhibitor | 0.125 0.015 DBMET03213 | DBMET03213 | |
| 0.027 | 0.019 | 0.037 | Protocollagen prolyl hydroxylase inhibitor | 0.037 0.009 DBMET03213 | DBMET03213 | |
| 0.023 | 0.02 | 0.024 | Phosphodiesterase 9A inhibitor | 0.024 0.017 DBMET03213 | DBMET03213 | |
| 0.067 | 0.063 | 0.1 | Protein kinase B beta inhibitor | 0.1 0.025 DBMET03213 | DBMET03213 | |
| 0.051 | 0.048 | 0.051 | MAP kinase kinase 9 inhibitor | 0.051 0.048 DBMET03213 | ||
| 0.076 | 0.076 | 0.078 | Factor XII inhibitor | 0.078 0.071 DBMET03213 | DBMET03213 | |
| 0.039 | 0.047 | 0.046 | Dipeptidyl peptidase IV inhibitor | 0.046 0.026 DBMET03213 | DBMET03213 | |
| 0.118 | 0.131 | 0.125 | Heat shock protein 90 alpha antagonist | 0.125 0.119 DBMET03213 | DBMET03213 | |
| 0.04 | 0.053 | 0.073 | Phosphatidylinositol 3-kinase beta inhibitor | 0.073 0.019 DBMET03213 | DBMET03213 | |
| 0.042 | 0.056 | 0.129 | Phosphatidylinositol 3-kinase delta inhibitor | 0.129 0.014 DBMET03213 | DBMET03213 | |
| 0.091 | 0.106 | 0.115 | Activin receptor-like kinase 4 inhibitor | 0.115 0.059 DBMET03213 | DBMET03213 | |
| 0.048 | 0.07 | 0.069 | Heat shock protein 90 beta antagonist | 0.069 0.029 DBMET03213 | DBMET03213 | |
| 0.121 | 0.146 | 0.156 | MAP kinase kinase 4 inhibitor | 0.156 0.051 DBMET03213 | DBMET03213 | |
| 0.17 | 0.202 | 0.196 | Immunomodulator | 0.196 0.169 DBMET03213 | DBMET03213 | |
| 0.041 | 0.074 | 0.048 | Dipeptidyl peptidase inhibitor | 0.048 0.047 DBMET03213 | DBMET03213 | |
| 0.096 | 0.13 | 0.155 | CDC-like kinase 1 inhibitor | 0.155 0.066 DBMET03213 | DBMET03213 | |
| 0.035 | 0.069 | 0.06 | Adenosine A1 receptor antagonist | 0.06 0.039 DBMET03213 | DBMET03213 | |
| 0.158 | 0.194 | 0.192 | Prostaglandin dehydrogenase inhibitor | 0.192 0.162 DBMET03213 | DBMET03213 | |
| 0.064 | 0.105 | 0.082 | CDK2/cyclin A inhibitor | 0.082 0.078 DBMET03213 | DBMET03213 | |
| 0.069 | 0.117 | 0.102 | Granulocyte macrophage colony stimulating factor antagonist | 0.102 0.069 DBMET03213 | DBMET03213 | |
| 0.053 | 0.103 | 0.073 | Calcium channel P-type blocker | 0.073 0.022 DBMET03213 | DBMET03213 | |
| 0.08 | 0.138 | 0.115 | Cyclooxygenase 2 inhibitor | 0.115 0.085 DBMET03213 | DBMET03213 | |
| 0.066 | 0.124 | 0.102 | Insulin receptor antagonist | 0.102 0.059 DBMET03213 | DBMET03213 | |
| 0.042 | 0.105 | 0.078 | Phosphodiesterase 4D inhibitor | 0.078 0.048 DBMET03213 | DBMET03213 | |
| 0.025 | 0.114 | 0.049 | mTOR inhibitor | 0.049 0.039 DBMET03213 | DBMET03213 | |
| 0.019 | 0.12 | 0.048 | Phosphatidylinositol 3-kinase alpha inhibitor | 0.048 0.039 DBMET03213 | DBMET03213 | |
| 0.053 | 0.166 | 0.081 | Phosphodiesterase I inhibitor | 0.081 0.074 DBMET03213 | DBMET03213 | |
| 0.07 | 0.19 | 0.138 | Activin receptor-like kinase 2 inhibitor | 0.138 0.077 DBMET03213 | DBMET03213 | |
| 0.159 | 0.285 | 0.187 | MAP kinase kinase 3 inhibitor | 0.187 0.165 DBMET03213 | DBMET03213 | |
| 0.051 | 0.196 | 0.087 | Phosphodiesterase 7B inhibitor | 0.087 0.075 DBMET03213 | DBMET03213 | |
| 0.06 | 0.213 | 0.118 | Src kinase inhibitor | 0.118 0.11 DBMET03213 | DBMET03213 | |
| 0.05 | 0.217 | 0.099 | mTOR complex 2 inhibitor | 0.099 0.034 DBMET03213 | DBMET03213 | |
| 0.036 | 0.221 | 0.099 | c-Src kinase inhibitor | 0.099 0.09 DBMET03213 | DBMET03213 | |
| 0.056 | 0.3 | 0.106 | Folate antagonist | 0.106 0.054 DBMET03213 | DBMET03213 | |
| 0.026 | 0.405 | 0.154 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.154 0.059 DBMET03213 | DBMET03213 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |